Remedy Robotics logo

Remedy Robotics

Develops AI-enabled robotic systems for endovascular intervention.

ShareLink copied

The record

Vertical
Devices & Robotics
Sub-segment
Endovascular robotics
Product type
Device
Stage
Series B
Headquarters
San Francisco, CA, United States
Region
North America

What they do

Remedy Robotics is developing the N1 System, an AI-enabled endovascular robotic platform and software suite for on-site, remote and potential autonomous intervention. On 16 November 2026 it announced a $62 million Series B led by DCVC, supporting clinical trials, work toward FDA approval and prototype deployment with clinical partners. The company explicitly states that N1 remains under development and is not available for sale or clinical use in any jurisdiction. Dr. David Bell is CEO and co-founder.

Investors

  • DCVC
  • UC Investments
  • Skip Capital
  • Hostplus
  • Build Collective
  • Blackbird
  • Divergent Capital
  • KdT Ventures

History and progression

How Remedy Robotics got here, step by step.

  1. 16 November 2026

    $62 million Series B

    DCVC led a $62 million Series B to support N1 clinical trials, development and work toward FDA approval.

Recent news

  1. 16 November 2026

    Remedy Robotics announcement
  2. 16 November 2026

    David Bell, CEO and Co-founder
  3. 16 November 2026

    Remedy Robotics Series B details

Related companies

Is this your company? Get a Verified profile